At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- IMVT-1402 (drug), IMVT-1402 (drug), Placebo (drug)
- How long the study runs
- Study runs about 23 months (dates as stated)
- About the drug or intervention
- IMVT-1402 — drug: Dose 1 for 26 weeks · IMVT-1402 — drug: Dose 2 for 26 weeks · Placebo — drug: For 26 weeks
- Patient visit burden
- Not specified by the sponsor
In plain English
This study is testing a medicine called IMVT-1402 in adults with Graves' disease, a condition where the immune system makes the thyroid gland overactive. The researchers want to find out how well the medicine works, and how safe and easy to tolerate it is. It is being run by Immunovant Sciences GmbH.
Who can take part
- Adults aged 18 or over, male or female.
- People diagnosed with Graves' disease who still have an overactive thyroid despite taking antithyroid drug treatment.
- Able to understand the study, give written consent, and follow the study procedures.
Who may not be able to
- People who have already been successfully treated with radioactive iodine or have had their thyroid gland fully removed by surgery.
- People with another autoimmune disease needing treatment that, in the researcher's view, would put them at too much risk.
- People with moderate-to-severe active thyroid eye disease who are expected to need surgery, corrective treatment, or medical therapy for it during the study.
What taking part involves
- • Not stated — ask the trial team.
Time commitment: Not stated — ask the trial team about how many visits there are, how long the study lasts, and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 18 Years to 75 Years
- Who
- All
- Number of participants
- 210
- Started
- 2025-06-19
- Last checked
- 2026-08
Plain English Summary
What is this study?
- • Testing a new treatment for graves' disease
- • Phase2 - 210 participants
- • This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment
Who can take part?
- • Ages 18 Years to 75 Years
- • Diagnosed with graves' disease
Where?
- • Cornwell - Site Number - 7009
- • London - Site Number - 7006
- • London - Site Number - 7001
- • Merthyr Tydfil - Site Number - 7003
- • +2 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 75 Years
- Who can join: All genders
What the study is looking for
- ✓Participants with the ability to understand the requirements of the trial, provide written agreement to take part, and...
- ✓Male or female participants aged ≥ 18 years.
- ✓Participants with diagnosis of GD who are hyperthyroid despite ATD treatment.
- ✓Other, more specific inclusion criteria are defined in the protocol.
Who cannot take part
- ✗Have previously been successfully treated with radioactive iodine (RAI) therapy or have undergone total thyroidectomy.
- ✗Have an autoimmune disease other than GD requiring treatment that, in the Investigator's judgment, puts the...
- ✗Additional exclusion criteria are defined in the protocol.
See the full criteria
Where Is This Study? (6 UK sites)
Site Number - 7009
Cornwell TR1 3LJ, United Kingdom
Site Number - 7006
London SE1 9RT, United Kingdom
Site Number - 7001
London W2 1NY, United Kingdom
Site Number - 7003
Merthyr Tydfil CF72 8XR, United Kingdom
Site Number - 7010
Salford M6 8HD, United Kingdom
Site Number - 7008
Surrey GU2 7XX, United Kingdom
How to Get in Touch
Central Study Contact
Sponsor contactCONTACT